Support and Resistance Levels
Past performance
About Kopran Ltd Kopran Ltd., established in 1958 and controlled by Parijat Enterprises, is a prominent player in the pharmaceutical industry, specializing in the production of pharmaceutical finished dosage forms and bulk drugs. Notably, it ranks among the top global producers of amoxycillin and is involved in the manufacturing of semi-synthetic penicillin and penicillin-G acylase. With FDA and UK regulatory approvals for its bulk drug plant, Kopran has a strong international presence, supported by technical collaborations with global entities such as Gesellschaft Fur Biotechnologische and Yuhan Corporation.
The company has a history of strategic expansions and product launches, including collaborations with E-Merck for co-marketing drugs like Rofecoxib and Cholestat. Kopran has enhanced its manufacturing capabilities significantly, increasing its liquid and tablet capacities. Acknowledged for its export growth, Kopran has received several accolades, including awards from CHEMEXCIL and the Ministry of Commerce. In recent developments, Kopran divested its API business to Kopran Research Laboratories Ltd. in 2015 to streamline operations and focus on core competencies.